Industries > Pharma > Ophthalmic Drugs: World Market Prospects 2013-2023

Ophthalmic Drugs: World Market Prospects 2013-2023

PUBLISHED: 27 March 2013
PAGES: 222
PRODUCT CODE:
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: N/A Categories: ,

How to find trends and revenue predictions for the ophthalmic drug industry

What are the commercial prospects for treating eye disorders? Visiongain's new report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for ocular drugs.

Our study lets you assess sales data at overall world market, submarket and national level. There you find that industry's most promising and lucrative segments, helping your research and analyses.

Therapies for treating eye disorders and diseases have rising demand. See the future of ophthalmic medicines and discover how sales of ocular drugs can increase.

Forecasts and other analyses to help you stay ahead in knowledge

In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (inc. SWOT), business outlooks and research and development (R&D). You receive 48 tables, 74 charts and 9 interviews.

Is finding commercial details a challenge? With our report you can get ahead in knowledge, benefiting your research, analyses and decisions. Find trends, innovations and opportunities. You see what's happening.

Discover areas that will prosper, reducing the risk of your being left behind.

The following sections show how you benefit from our new study.

Discover prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets:
• Glaucoma treatments
• Anti-allergy, anti-inflammatory and anti-infective agents
• Retinal disorder treatments
• Dry eye treatments
• Other medicines.

With our investigation you gain business research and analysis with individual sales predictions and discussions. You find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success.

You can gain competitive advantages by understanding the trends, opportunities and challenges facing the ophthalmic drug market.

See revenue forecasts for products

How will leading ophthalmic drugs perform to 2023 at world level? Our work shows you revenue forecasts for 20 top products, including Lucentis, Eylea, Visudyne, Xalatan/Xalacom, Patanol and Restasis.

Discover how high revenues can go, to 2023, finding areas and years with highest predicted growth. You see what's happening, understanding trends, challenges and opportunities.

Our work also breaks the main world forecast into leading geographical markets.

What prospects for leading countries?

Developments worldwide will influence the market, especially rising demand in emerging countries. Our report shows outlooks for the industry.

You see individual forecasts to 2023 for ten national markets, getting overall revenues:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, India and China

Discover progress and outlooks. You assess the industry's future – hear about developments and find their significance.

You find potential. Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change medical prescribing and the commercial landscape.

Research and development – assess innovation, trends and possibilities

What about R&D – the pipeline for new drugs? You see trends for these areas:
• Glaucoma treatments
• Anti-allergy, anti-inflammatory and anti-infective agents
• Retinal disorder treatments
• Dry eye treatments
• Other progress in ophthalmic treatments.

Our study also discusses these candidates and others:
• Neuroprotective agents
• RNA interference technology
• Ocular implants
• Gene therapy.

There's strong, promising R&D for treating ocular disorders. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. See what's happening.

What affects ophthalmic drugs treatments from 2013?

Our report discusses issues and events affecting that industry and market from 2013 onwards:
• Increasing prevalence of eye disorders
• Reimbursement for ophthalmic pharmaceuticals
• Patient compliance
• Generic competition.

Also, we discuss these aspects of the field:
• Development of new drug delivery methods and formulations
• Sustained-release ocular Implants
• New ophthalmic therapeutic applications for drugs.

See what the future holds. You investigate technological, economic and political matters, finding emphasis on companies, competition and business outlooks.

Leading companies and 2015 market value

We predict the overall world market for ophthalmic drugs will reach $21.9bn in 2015, and expand further to 2023.

What are leading companies doing? Our work discusses Allergan, Novartis, Pfizer, Roche and other pharmaceutical companies, evaluating prospects of the industry and market.

Prospects for R&D are strong, and from 2013 onwards there will arise many opportunities. Our work shows you the technological and commercial possibilities, helping you stay ahead.

Eight ways Ophthalmic Drugs: World Market Prospects 2013-2023 helps

To sum up, our investigation gives you the following knowledge:
• Revenues to 2023 for the overall world market and 5 submarkets – you discover that industry's prospects
• Forecasting to 2023 for the US, Japan, Germany, France, UK, Spain, Italy, Brazil, India and China – you see leading national sales potentials
• Discover revenue forecasts to 2023 for 20 leading products — you find sales outlooks for top brands
• Review R&D, seeing pipeline trends by therapeutic area – you hear about progress in those research areas, finding technological and medical possibilities
• Opinions on the sector – you read our industry interviews
• Understanding of competition and opportunities – you see what affects that industry, learning what shapes its future
• Analysis of what stimulates and restrains the industry and market – you assess challenges and strengths
• Prospects for established firms and those seeking to enter the sector – you explore needs, practices and outlooks for success.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for insight.

You see prospects for ophthalmic drugs by ordering now

Visiongain's new study is for everyone needing analysis of the industry and market for ophthalmic medicines. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Ophthalmic Drugs: World Market Prospects 2013-2023


Download sample pages

Complete the form below to download your free sample pages for Ophthalmic Drugs: World Market Prospects 2013-2023


Latest Pharma news

Visiongain Publishes Pharmaceutical Spray Drying Market Report 2021-2031

The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.

25 October 2021

READ

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Categories